Psychedelic Spotlight News

  • MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

    Listen, Videos

    MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock

    Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/

    All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.

    Follow us on Twitter:
    The Psychedelic Investor: @psycInvestor
    James: @Psy_Invest
    Maria: @psy_holy
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
    https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64

    COUPON CODE: PSYCHSPOTLIGHT15

    Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

    In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.

    The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.

    Some of the questions MindMed is trying to answer are:

    Can Psychedelics treat Mental Health conditions?

    Can Psychedelics treat depression?

    Can Psychedelics treat anxiety?

    Can Psychedelics treat ADHD?

    Can Psychedelics help with Autism?

    Can Psychedelics help treat pain?

    #MindMed #MNMD #MindMedStocks

  • Two Psychedelic Companies Run Out of Money: Will it Cause a Domino Effect? | Plus MindMed Stock News

    Listen, Videos

    Two Psychedelic Medicines Companies Run out of Money. What is next for psychedelic stocks? Plus a MindMed Stock Update( MMED / MMED)

    Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/

    Follow us on Twitter:
    @Psy_Invest
    @psy_holy
    @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC

    A second domino is falling in the world of psychedelic stock investing.

    Last week, Psychedelic Spotlight reported that Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) was halting its psychedelic medicines research, following a “strategic review” undertaken by the company.

    In short, they ran out of money.

    As I have stated repeatedly, running a psychedelic research company is ridiculously expensive, and many smaller companies with low market caps and little money in the bank will find it hard to survive in a market context of low stock prices.

    At the time, I speculated that “we shouldn’t be surprised if this is just the first domino,” and unfortunately, it didn’t take much time for the prophecy to be realized.

    On March 19th, psychedelics company Core One Labs (CSE: COOL) (OTC: CLABF) announced that they are “working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.”

    Or, in other words, they too have run out of money and are looking for a financial savior.

    This wasn’t particularly surprising. Taking a cursory look at their financials, we can see the dire position the company is in. As of the end of September, the company had $587,000 CAD in the bank, and they were spending more than $5 million per quarter. With a market cap of around $32 million, Core One would have to dilute their stock by more than 15% each quarter to keep spending at the same levels. This, obviously, is an unsustainable proposition.

    So, with two psychedelic medicine companies essentially announcing that they no longer have the financial wherewithal to continue operations, does it mean that the end of psychedelic stocks is near?

    No, it most certainly does not.

    To start, we need to understand that the psychedelics companies that are beginning to falter are the ones who were already in bad financial shape. There are many companies that have strong financials, and do not need to worry about refinancing any time soon. A short and non-exhaustive list of these companies include: atai Life Sciences (Nasdaq: ATAI); MindMed (Nasdaq: MNMD) (NEO: MMED); and Small Pharma (TSXV: DMT) (OTCQB: DMTTF). Even if — and I judge this to be likely — more small-cap psychedelics companies follow Mind Cure and Core One Labs’ lead, the more financially stable companies won’t be affected.

    Sources:

    PsychedelicSpotlight.com article: https://psychedelicspotlight.com/another-psychedelics-company-core-one-labs-is-crashing-is-industry-in-trouble/

    MindCure Press release: https://www.newswire.ca/news-releases/mindcure-provides-update-on-strategic-review-891232484.html

    Core One Labs Press Release: https://www.globenewswire.com/news-release/2022/03/19/2406329/0/en/Core-One-Labs-to-Investigate-Soliciting-Investment-and-Potential-Takeover-Opportunities.html

    Core One Labs $100/ gram psilocybin: https://www.globenewswire.com/news-release/2022/02/23/2390219/0/en/Vancouver-discovery-will-make-Magic-Mushroom-mental-health-care-cheaper.html

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #PsychedelicStocks #Psychedelics #Investing